Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Atossa Therapeutics Announces Discovery of Synergistic Compounds for (Z)-Endoxifen in Breast Cancer Treatment Quiver Quantitative, Inc. - Thu Dec 12, 5:24PM CST

Atossa Therapeutics announced data on new compounds potentially effective in combination with (Z)-endoxifen for breast cancer treatment.Quiver AI SummaryAtossa Therapeutics, Inc. announced the discovery...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium GlobeNewswire - Thu Dec 12, 7:15AM CST

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density GlobeNewswire - Wed Dec 11, 7:15AM CST

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Presents Promising Phase 2 EVANGELINE Trial Data on (Z)-Endoxifen for Breast Cancer at SABCS 2024 Quiver Quantitative, Inc. - Tue Dec 10, 6:26PM CST

Atossa Therapeutics presents Phase 2 EVANGELINE trial data on (Z)-endoxifen at SABCS 2024, focusing on breast cancer treatment.Quiver AI SummaryAtossa Therapeutics, Inc. has announced the presentation...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium GlobeNewswire - Tue Dec 10, 8:05AM CST

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Presents Research on Anti-Cancer Activity of (Z)-Endoxifen and Byproducts at AACR Special Conference Quiver Quantitative, Inc. - Mon Dec 9, 5:22PM CST

Atossa Therapeutics presented research on (Z)-endoxifen's anti-cancer effects at the AACR conference, highlighting potential treatment options.Quiver AI SummaryAtossa Therapeutics, Inc. announced the presentation...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research GlobeNewswire - Mon Dec 9, 7:15AM CST

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research GlobeNewswire - Thu Nov 21, 7:30AM CST

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Announces Five Abstracts Accepted for Presentation at SABCS 2024 Featuring (Z)-Endoxifen Data in Breast Cancer Research Quiver Quantitative, Inc. - Wed Nov 20, 5:52PM CST

Atossa Therapeutics announced five accepted abstracts on (Z)-endoxifen for the San Antonio Breast Cancer Symposium in December 2024.Quiver AI SummaryAtossa Therapeutics, a clinical-stage biopharmaceutical...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium GlobeNewswire - Wed Nov 20, 7:30AM CST

ATOS : 0.9637 (-1.66%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot